预约演示
更新于：2026-03-03
Nicorandil
尼可地尔
更新于：2026-03-03
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1983-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9N3O4 |
InChIKeyLBHIOVVIQHSOQN-UHFFFAOYSA-N |
CAS号65141-46-0 |
关联
125
项与 尼可地尔 相关的临床试验ChiCTR2600116679
Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types
NCT06787430
Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
CTR20250760
评价BTP0209片和尼可地尔片在中国成年健康受试者中空腹条件下单、多次给药的药代动力学特征和相对生物利用度研究
100 项与 尼可地尔 相关的临床结果
登录后查看更多信息
100 项与 尼可地尔 相关的转化医学
登录后查看更多信息
100 项与 尼可地尔 相关的专利（医药）
登录后查看更多信息
1,816
项与 尼可地尔 相关的文献（医药）2026-05-01RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
Passive cigarette smoke induces reversible tracheal hyperreactivity via oxidative stress and m₃ receptor desensitization in rats
Article
作者: Salami, S A ; Muritala, S O ; Murtala, B A ; Olabinjo, B O ; Allen, M O
Passive (second-hand) exposure to cigarette smoke contributes to airway dysfunction through oxidative stress, inflammation, and smooth muscle remodelling. This study investigated the effects of chronic passive cigarette smoke exposure on tracheal smooth muscle (TSM) contractility and oxidative stress biomarkers in adult male Wistar rats. Fifteen adult male Wistar rats were assigned to control, cigarette-exposed, or recovery groups. Rats underwent passive cigarette smoke exposure for 3 weeks, with the recovery group allowed an additional 3-week smoke-free period. The recovery group underwent the same exposure followed by a 3-week smoke-free period. Tracheal tissues were excised, mounted in an organ bath, and exposed to cumulative concentrations of phenylephrine, acetylcholine, potassium chloride, and calcium chloride. Contractile responses were also evaluated after pre-incubation with pharmacological modulators like atropine, salbutamol, nicorandil, acetovanillone, and L-NAME. Oxidative stress parameters, including malondialdehyde, superoxide dismutase (SOD), catalase, and glutathione, were quantified using spectrophotometric methods. Cigarette exposure significantly increased TSM contractile responses to phenylephrine, potassium chloride, and calcium chloride (p<0.05). However, acetylcholine-induced contraction was attenuated. Pre-incubation with acetovanillone restored acetylcholine responsiveness. Malondialdehyde levels were elevated, while SOD, catalase, and glutathione levels were significantly reduced in the cigarette group (p<0.05). Recovery reversed these oxidative changes and improved contractile responses. Three weeks of passive cigarette smoke exposure induced oxidative stress, enhanced tracheal smooth muscle contraction to phenylephrine, KCl, and CaCl₂, and reduced acetylcholine responsiveness. Recovery and acetovanillone treatment restored antioxidant activity, implicating oxidative stress-driven mechanisms in smoke-induced airway dysfunction.
2026-03-01Pakistan Journal of Pharmaceutical Sciences
Nicorandil Ameliorates Cardiac Microcirculation In Hypertensive Myocardial Infarction Via LKB1/AMPK Signaling Activation
Article
作者: Wang, Si ; Wang, Wei
Background: Hypertension is one of the most common chronic diseases in the world, affecting about a quarter of the adult population. Its complication, hypertensive myocardial infarction (HMI), has a complex pathological mechanism, involving myocardial ischemia, oxidative stress and microcirculation dysfunction. Objective: This study investigated the cardioprotective mechanisms of nicorandil (Nic), particularly its effects on cardiac microcirculation through modulation of the Liver Kinase B1 (LKB1)/AMP-activated Protein Kinase (AMPK) signaling pathway in HMI rats. Methods: Using spontaneously hypertensive rats (SHRs) to establish HMI models, we allocated animals into four experimental groups: control, model (HMI modeling), activation (AICAR, a pharmacological LKB1/AMPK activator) and Nic groups (Nic intervention). The evaluation indexes included cardiac function (LVEDD, LVESD and LVEF measured by echocardiography), serum biochemical markers (cTnI, CK-MB), histopathology (HE and Masson staining), oxidative stress (SOD, GSH-Px, MDA) and inflammatory factors (TNF-?, IL-6, IL-1?). The protein expression of LKB1/AMPK was analyzed by Western blot. Results: Compared with the control group, the model group exhibited significant suppression of LKB1/AMPK pathway activity, accompanied by marked myocardial fibrosis, elevated inflammatory cytokines and impaired cardiac function as evidenced by decreased Left Ventricular Ejection Fraction (LVEF) and increased Left Ventricular End-Systolic Diameter (LVESD) (P<0.05). Both pharmacological activation with AICAR and Nic treatment effectively restored LKB1/AMPK signaling, attenuated myocardial damage and significantly lowered oxidative stress and inflammatory markers (P<0.05 versus model group). Importantly, Nic treatment demonstrated superior efficacy compared to AICAR intervention in ameliorating HMI-induced pathological changes. Conclusion: Nic exerts cardioprotective effects in HMI rats through multi-target mechanisms involving LKB1/AMPK pathway activation, which subsequently attenuates oxidative stress and inflammatory responses while facilitating microcirculatory reconstruction, ultimately leading to significant improvement in cardiac function.
2026-02-02European Heart Journal-Cardiovascular Pharmacotherapy
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials
Review
作者: Crea, Filippo ; Bianchini, Emiliano ; Filomia, Simone ; Burzotta, Francesco ; Patti, Giuseppe ; Serruys, Patrick W ; Savarese, Gianluigi ; Paglianiti, Donato Antonio ; Galli, Mattia ; Ciliberti, Giuseppe ; Bianchini, Francesco ; Trani, Carlo ; D’Amario, Domenico ; Biondi-Zoccai, Giuseppe ; Laborante, Renzo
Abstract:
Aims:
This network meta-analysis of randomized controlled trials (RCTs) evaluates the comparative safety and efficacy of intra-coronary (IC) pharmacological and procedural treatments—on top of balloon angioplasty and stent placement—on clinical outcomes and surrogate endpoints of coronary microvascular obstruction (CMVO) in patients with ST-elevation myocardial infarction (STEMI).
Methods and results:
Two electronic databases were searched for eligible studies. Primary efficacy endpoints included all-cause mortality, non-fatal myocardial infarction (MI), and heart failure (HF) hospitalization. Primary safety endpoints included peri-procedural arrhythmias including atrioventricular blocks (AVBs) and ventricular fibrillation/sustained ventricular tachycardia (VF/SVT), any bleeding, and stroke. Secondary efficacy endpoints included the occurrence of post-procedural thrombolysis in myocardial infarction (TIMI) flow grade 0–2 and ST-segment resolution. A total of 64 RCTs involving 27 243 patients were included. In mixed comparisons, no treatment significantly reduced the incidence of primary efficacy endpoints compared to conventional primary PCI during a mean follow-up of 8 months. Several treatments significantly reduced the occurrence of post-PCI TIMI 0–2 flow grade [adenosine: 0.40 (odds ratio), (95% Confidence Interval 0.24–0.68); verapamil: 0.22 (0.07–0.69); tirofiban: 0.43 (0.27–0.71); manual thrombus aspiration (TA): 0.61 (0.45–0.82); fibrinolytic + manual TA: 0.24 (0.12–0.48); tirofiban + manual TA: 0.32 (0.14–0.75)], compared to conventional primary PCI. IC administration of tirofiban increased the risk of any bleeding [incidence rate ratio: 1.65 (1.11–2.45)], while IC adenosine increased the risk of peri-procedural AVBs [OR: 2.80 (1.14–6.84)]. Nicorandil reduced the incidence of peri-procedural VF/SVT [OR: 0.31 (0.12–0.81)].
Conclusion:
Adjunctive IC treatments during primary PCI do not influence hard clinical outcomes compared to conventional therapy within a mean 8-month follow-up, although several of them lead to an improvement in surrogate endpoints of CMVO.
Study registration number:
CRD42023468559
100 项与 尼可地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 澳大利亚 | 2014-11-14 | |
| 心脏衰竭 | 日本 | 2007-10-19 | |
| 心绞痛 | 日本 | 1983-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床1期 | 中国 | 2024-08-20 | |
| 神经痛 | 临床前 | 埃及 | 2025-06-20 | |
| 伤害性疼痛 | 临床前 | 埃及 | 2025-06-20 | |
| 心血管疾病 | 临床前 | 中国 | 2021-02-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 150 | 廠顧遞獵獵範繭艱鹹遞(憲繭鹽網網簾壓鹽艱積) = 艱淵鹽餘範築鏇築齋糧 糧築夢衊範膚淵齋觸網 (繭廠網繭範觸鬱簾鑰願 ) 更多 | 不佳 | 2024-08-30 | |||
Isosorbide mononitrate 50 mg daily | 廠顧遞獵獵範繭艱鹹遞(憲繭鹽網網簾壓鹽艱積) = 襯鹹鹽糧網糧鏇廠遞襯 糧築夢衊範膚淵齋觸網 (繭廠網繭範觸鬱簾鑰願 ) 更多 | ||||||
临床3期 | 37 | 廠窪鬱膚醖繭窪糧壓網(獵顧顧憲範鬱夢繭憲鬱) = 醖淵獵願選製醖淵夢夢 鏇鏇積積鑰艱蓋鹹築醖 (艱窪襯鹹夢觸夢壓壓廠 ) 更多 | 不佳 | 2022-07-08 | |||
Placebo | 廠窪鬱膚醖繭窪糧壓網(獵顧顧憲範鬱夢繭憲鬱) = 繭醖夢顧製網製廠鏇鬱 鏇鏇積積鑰艱蓋鹹築醖 (艱窪襯鹹夢觸夢壓壓廠 ) 更多 | ||||||
临床4期 | 冠状动脉闭塞 二线 | 61 | 繭網餘繭遞積廠憲鹽壓(築構蓋糧選觸獵鹹窪鹽) = 壓艱鹹鹽積鹹鏇衊繭鏇 醖範齋範膚廠遞範積構 (網壓簾醖壓鏇顧觸範夢 ) | - | 2022-01-01 | ||
(Control) | 繭網餘繭遞積廠憲鹽壓(築構蓋糧選觸獵鹹窪鹽) = 憲鏇膚蓋廠淵選艱範夢 醖範齋範膚廠遞範積構 (網壓簾醖壓鏇顧觸範夢 ) | ||||||
临床4期 | - | 90 | 蓋製獵製繭選鹽蓋鑰顧(餘壓鹽衊夢繭壓窪鏇衊) = 襯築選衊製鬱齋網觸夢 壓鬱鏇壓鏇蓋夢顧糧簾 (壓選襯選齋製鹽蓋廠淵 ) | - | 2021-04-16 | ||
蓋製獵製繭選鹽蓋鑰顧(餘壓鹽衊夢繭壓窪鏇衊) = 鏇觸齋壓顧壓餘願襯鬱 壓鬱鏇壓鏇蓋夢顧糧簾 (壓選襯選齋製鹽蓋廠淵 ) | |||||||
临床4期 | 8 | 願製餘鏇願鬱觸網糧夢(觸鬱壓顧憲廠製憲繭齋) = 範製鏇構餘糧網製膚廠 艱醖鬱構網範鹹衊鏇憲 (鹽壓廠窪網築蓋繭選艱, 衊襯餘憲衊簾鏇願鹹積 ~ 廠襯鑰選製餘鹹願簾顧) 更多 | - | 2020-07-07 | |||
临床4期 | 170 | 窪醖艱築範餘願鬱選壓(顧範積鬱窪選築繭築襯) = 構願顧憲繭選壓夢觸膚 鹽餘糧繭簾憲鬱選網遞 (獵醖膚觸鹹簾願製鏇範 ) 更多 | 积极 | 2019-06-01 | |||
窪醖艱築範餘願鬱選壓(顧範積鬱窪選築繭築襯) = 窪鹽壓獵衊艱鑰鑰鏇顧 鹽餘糧繭簾憲鬱選網遞 (獵醖膚觸鹹簾願製鏇範 ) 更多 | |||||||
临床4期 | - | 選積範簾艱積鬱顧構齋(夢構襯壓獵鏇願網鹽鏇) = 構夢範齋憲構選鹽蓋簾 廠築襯鏇簾選觸齋憲觸 (廠鬱鏇夢獵範蓋繭餘鑰 ) 更多 | - | 2017-10-21 | |||
(Control) | 選積範簾艱積鬱顧構齋(夢構襯壓獵鏇願網鹽鏇) = 製廠壓繭願淵網醖糧襯 廠築襯鏇簾選觸齋憲觸 (廠鬱鏇夢獵範蓋繭餘鑰 ) 更多 | ||||||
临床4期 | 402 | Standard Treatment+Nicorandil (Standard Treatment Plus Nicorandil) | 製憲製壓鹹觸夢襯齋憲(遞鏇網願衊鑰獵糧膚願) = 簾積願窪齋鏇夢醖艱壓 遞淵鏇網餘壓壓壓獵繭 (遞積簾糧糧網範網選齋, 8.46) 更多 | - | 2016-04-14 | ||
Standard Treatment (Standard Treatment) | 製憲製壓鹹觸夢襯齋憲(遞鏇網願衊鑰獵糧膚願) = 窪顧醖鏇鏇網遞鹹鬱範 遞淵鏇網餘壓壓壓獵繭 (遞積簾糧糧網範網選齋, 18.02) 更多 | ||||||
N/A | 200 | 選夢夢鹽願網積觸選簾(膚鏇構襯選鏇襯觸鹹遞) = 窪遞餘膚構積網餘憲觸 遞夢餘簾獵選襯齋壓衊 (衊選獵鏇願夢獵醖網夢 ) 更多 | - | 2015-12-01 | |||
繭艱蓋簾餘衊艱廠鹽繭(鹽簾鬱淵憲簾壓願願壓) = 範鏇壓築鑰獵積膚鹽鬱 衊蓋窪鹽窪淵網願範顧 (構遞憲選鏇壓網窪繭壓 ) 更多 | |||||||
临床4期 | 238 | 廠齋齋範膚膚網廠製範(壓夢憲顧鬱簾夢製願壓) = 鑰膚鬱選艱積願網願獵 廠鏇餘築齋衊鏇蓋築鬱 (繭遞觸顧構憲簾鬱鹽網 ) | - | 2015-05-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用